(Total Views: 676)
Posted On: 08/01/2020 5:16:01 PM
Post# of 36568
NuGenerex IO Clinical Pipeline in
High-Value Markets
1. AE37 plus Keytruda in TNBC – enrolling patients
• The market value for HER2-negative breast cancer therapeutics will increase more than
fourfold, from $1.45 billion in 2013 to an estimated $6.12 billion by 2023 – Global Data
2. AE37 + checkpoint inhibitor in bladder/urothelial cancer – protocol development
• The global bladder/urothelial cancer drug market size is expected to reach $3.6 billion by 2023
- Grand View Research, Inc.
3. Ii-Key-GP100 (48-58) & Ii-Key-Tyr (370-381) in melanoma – planning stage
• The global melanoma therapeutics market is expected to reach $12.4 billion by 2025 - Grand
View Research, Inc.
4. Ii-Key-SARS-CoV-2 – preclinical ex-vivo human study of COVID-19 patients
• The US Market for a COVID-19 vaccine is estimated to worth multiple billions
5. Ii-Key-HA for G4 EA H1 Swine Flu – planning stage with China CDC
• Goal to establish a pandemic vaccine response platform with China CDC using Ii-Key to stop
pandemic threats at their source
High-Value Markets
1. AE37 plus Keytruda in TNBC – enrolling patients
• The market value for HER2-negative breast cancer therapeutics will increase more than
fourfold, from $1.45 billion in 2013 to an estimated $6.12 billion by 2023 – Global Data
2. AE37 + checkpoint inhibitor in bladder/urothelial cancer – protocol development
• The global bladder/urothelial cancer drug market size is expected to reach $3.6 billion by 2023
- Grand View Research, Inc.
3. Ii-Key-GP100 (48-58) & Ii-Key-Tyr (370-381) in melanoma – planning stage
• The global melanoma therapeutics market is expected to reach $12.4 billion by 2025 - Grand
View Research, Inc.
4. Ii-Key-SARS-CoV-2 – preclinical ex-vivo human study of COVID-19 patients
• The US Market for a COVID-19 vaccine is estimated to worth multiple billions
5. Ii-Key-HA for G4 EA H1 Swine Flu – planning stage with China CDC
• Goal to establish a pandemic vaccine response platform with China CDC using Ii-Key to stop
pandemic threats at their source
(2)
(0)
